Business
Edgewise Therapeutics Announces Pricing of Upsized Public Offering of Common Stock
BOULDER, Colo.--(BUSINESS WIRE)-- Edgewise Therapeutics, Inc. (NASDAQ: EWTX) today announced the pricing of its upsized underwritten public offering of
About this update from Edgewise Therapeutics, Inc.
[{"type":"text","content":" BOULDER, Colo.--(BUSINESS WIRE)--\nEdgewise Therapeutics, Inc. (NASDAQ: EWTX) today announced the pricing of its upsized underwritten public offering of 11,627,907 shares of its common stock at a price to the public of $10.32 per share. All of the shares are to be sold by Edgewise Therapeutics. In addition, Edgewise Therapeutics has granted the underwriters a 30-day option to purchase up to an additional 1,744,186 shares of its common stock. Before deducting the underwriting discounts and commissions and offering expenses, Edgewise Therapeutics expects to receive total gross proceeds of $120 million, assuming no exercise of the underwriters’ option to purchase additional shares. The offering is expected to close on or about September 16, 2022, subject to satisfaction of customary closing conditions.\n\nJ.P. Morgan and SVB Securities are acting as joint book-running managers for the offering. Wedbush PacGrow is acting as lead manager for the offering.\n\nEdgewise Therapeutics filed a Registration Statement on Form S-3, which was declared effective by the SEC, and has filed a preliminary prospectus supplement and accompanying prospectus relating to the offering. A final prospectus supplement and accompanying prospectus relating to the offering will also be filed with the SEC. These documents can be accessed for free through the SEC’s website at www.sec.gov.\n\nWhen available, copies of the final prospectus supplement and the accompanying prospectus relating to this offering may also be obtained from:\n\nJ.P. Morgan Securities LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, telephone: 1-866-803-9204 or by email: [email protected]; or\n\nSVB Securities LLC, Attn: Syndicate Department, 53 State Street, 40th Floor, Boston, Massachusetts 02109, by telephone at 1-800-808-7525, ext. 6105, or by email at [email protected].\n\nThis press release does not constitute an offer to sell or a solicitation of an offer to buy, nor will there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation, or sale would be unlawful before registration or qualification under the securities laws of that state or jurisdiction.\n\nAbout Edgewise Therapeutics\n\nEdgewise Therapeutics is a clinical-stage biopharmaceutical company focused on the discovery, de...